Using MRI scans to target biopsies is more effective at detecting prostate cancers that are likely to need treatment than standard ultrasound guided biopsies alone, according to research published in JAMA Network Open. The research, led by the National Institute for Health Research (NIHR) and Universities of Bristol, Ottawa, Exeter and Oxford, combined the results from seven studies covering…
Prostate-specific membrane antigen imaging should be the positron emission tomography imaging agent of choice for men who have a prostate cancer recurrence after radical prostatectomy, which needs to be detected and located. For these men, it should become the standard of care, new research shows.
Wilmot Cancer Institute scientists believe they have figured out why a commonly used drug to treat late-stage prostate cancer often stops working after four or five months and appears to have a dual function that later turns the cancer into a relentless aggressor.
Pathologists, radiologists, urologists and radiotherapy specialists sit at the core of the treatment pathway for the patient, working together as a cohesive unit. In an innovative 2019 ECR session in Vienna, the prostate unit from Ghent University Hospital in Belgium outlined how the team works to deliver the best clinical outcome for patients. Session chair Professor Geert M Villeirs of Ghent…
Cancer is a genetic disease caused by abnormal changes over time to genes that control cell function, typically starting in a single cell (an acquired mutation) and often not linked to an inherited genetic mutation. In other words, most cancers happen by chance. Only about 5 to 10 percent of cancers are due to an inherited genetic mutation, says Monique Lubaton, MGC, CGC, cancer genetic counselor…
Prostate cancer is one of the most common cancers diagnosed nationally among men. The National Cancer Institute estimates 161,000 were diagnosed in 2017. While there are many treatment options for men with prostate cancer, a recent national study published in the Journal of the American Medical Association compared the effectiveness of treatments for high-risk prostate cancer. Said Daniel Krauss,…
One of the biggest challenges in treating prostate cancer is distinguishing men who have aggressive and potentially lethal disease from men whose cancer is slow-growing and unlikely to metastasize. For years, prostate-specific antigen (PSA) level, cancer grade and tumor stage have been used to sort prostate cancer patients into risk groups established by the National Comprehensive Cancer Network.…
A study published in Prostate Cancer and Prostatic Diseases demonstrated that physicians elected to perform fewer biopsies when Prostate Health Index (phi) testing was included in their overall, routine, clinical assessment. Phi testing is recommended for men presenting with elevated serum total prostate-specific antigen (PSA) in the 4-10 ng/mL range and a non-suspicious digital rectal exam…
The new product solutions of medical technology company Richard Wolf were presented at the Congress of the European Association of Urology (EAU) in several live operations and pre-recorded videos.
University of Adelaide researchers have uncovered a new pathway which regulates the spread of prostate cancer around the body.
The prostate remains the only organ where random biopsies are performed to find cancer, notes Jean-Michel Correas MD PhD, from the Necker University Hospital in Paris. If we proposed this approach to a woman to search for breast cancer, it would be outrageous, he said.
In mid-2015 the second generation of the ultrasound system H60 and the Urostation Touch was launched. At the Urology Department of the Hospital Fürth in Fürth, Germany the H60 and Urostation Touch are already being successfully used with 4 to 5 patients a week for prostate diagnostics.
One in six men will develop prostate cancer. It is the second leading cause of cancer death amongst men in both the US and the EU. Definite diagnosis at an early stage is vital for survival and early treatment minimizes the risk of adverse effects, such as incontinence, erectile dysfunction, or impotence. While there is no preventive screening there is a ray of hope. Prof. Jelle Barentsz,…
What you see is what you get - unfortunately, this doesn’t always apply in cancer imaging. Why is it that something which looks conspicuous on an image later turns out not to be a tumour? Why, on the other hand, are things overlooked that later turn out to be cancer? Pathological findings are extremely important to help improve diagnostic precision in radiology. Both disciplines therefore…
Pathology is the gold standard of prostate diagnostics. Whilst the radiologist makes interpretations based on shadows and grey scale values visible on an image, the pathologist has the ‘fait accompli’ under the microscope. Professor Glen Kristiansen, Director at the Institute for Pathology at the University Hospital Bonn, explains why image-guided biopsies also make sense from the…